From the proximity analysis, we found that certain drugs targeting SLC6A4 and SLC6A2 (which have been associated with selective serotonin reuptake inhibitors (SSRIs) [41,42,43,44]) were closely related to the “PD disease network”. The gene discussed is SLC6A2; the disease is Parkinson disease.